Symbols / APLM Stock $13.79 -3.57% Apollomics, Inc.

Healthcare • Biotechnology • United States • NCM
APLM (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Hung-Wen Chen
Exch · Country NCM · United States
Market Cap 30.28M
Enterprise Value 28.77M
Income -10.94M
Sales 8.84M
FCF (ttm) -9.81M
Book/sh -1.49
Cash/sh 1.49
Employees 14
Insider 10d —
IPO Nov 26, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -21.22
PEG —
P/S 3.42
P/B -9.29
P/C —
EV/EBITDA -3.17
EV/Sales 3.25
Quick Ratio 0.91
Current Ratio 0.96
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -7.57
EPS next Y -0.65
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA -57.61%
ROE -13.05%
ROIC —
Gross Margin 100.00%
Oper. Margin 4.32%
Profit Margin -123.72%
Shs Outstand 2.20M
Shs Float 1.26M
Insider Own 53.32%
Instit Own 0.03%
Short Float 0.14%
Short Ratio 0.20
Short Interest 1.59K
52W High 42.12
vs 52W High -67.26%
52W Low 3.66
vs 52W Low 276.88%
Beta 1.53
Impl. Vol. —
Rel Volume 0.58
Avg Volume 7.57K
Volume 4.39K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $14.30
Price $13.79
Change -3.57%
About

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$13.79
Latest analyst target
3. DCF / Fair value
$-80.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.79
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-05-08 main HC Wainwright & Co. Buy → Buy $2
2024-04-01 main EF Hutton Buy → Buy $7
2024-04-01 main HC Wainwright & Co. Buy → Buy $5
2023-11-20 reit HC Wainwright & Co. Buy → Buy $17
2023-10-03 main HC Wainwright & Co. Buy → Buy $17
2023-06-05 reit HC Wainwright & Co. Buy → Buy $18
2023-06-01 init HC Wainwright & Co. — → Buy $18
2023-04-25 init EF Hutton — → Buy $25
News
RSS: Latest APLM news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-15 HUANG YA-CHI Director — 500 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
8.50
0.00
0.00
0.00
Operating Revenue
8.50
0.00
0.00
0.00
Operating Expense
17.69
-57.90%
42.03
-22.69%
54.37
+22.49%
44.39
Research And Development
5.53
-77.49%
24.57
-28.15%
34.19
-3.56%
35.46
Selling General And Administration
12.44
-29.98%
17.77
-13.92%
20.64
+107.51%
9.95
General And Administrative Expense
12.44
-29.98%
17.77
-13.92%
20.64
+107.51%
9.95
Other Gand A
12.44
-29.98%
17.77
-13.92%
20.64
+107.51%
9.95
Other Operating Expenses
-0.28
+7.31%
-0.30
+35.13%
-0.46
+54.33%
-1.02
Total Expenses
17.69
-57.90%
42.03
-22.69%
54.37
+22.49%
44.39
Operating Income
-9.19
+78.13%
-42.03
+22.69%
-54.37
-22.49%
-44.39
EBITDA
-10.62
+79.99%
-53.06
+69.11%
-171.77
+28.41%
-239.94
Normalized EBITDA
-8.76
+78.32%
-40.40
+76.75%
-173.78
+27.42%
-239.44
Reconciled Depreciation
0.26
-29.36%
0.36
-46.04%
0.67
-13.68%
0.78
EBIT
-10.87
+79.65%
-53.42
+69.02%
-172.44
+28.36%
-240.72
Total Unusual Items
-1.86
+85.32%
-12.66
-729.08%
2.01
+497.63%
-0.51
Total Unusual Items Excluding Goodwill
-1.86
+85.32%
-12.66
-729.08%
2.01
+497.63%
-0.51
Special Income Charges
-1.72
+86.79%
-13.00
0.00
0.00
Impairment Of Capital Assets
1.72
-86.79%
13.00
0.00
0.00
Net Income
-10.94
+79.69%
-53.86
+68.80%
-172.60
+28.33%
-240.81
Pretax Income
-10.94
+79.60%
-53.60
+68.94%
-172.59
+28.33%
-240.81
Net Non Operating Interest Income Expense
0.09
-71.10%
0.30
-50.08%
0.60
+78.40%
0.34
Interest Expense Non Operating
0.07
-63.69%
0.18
+19.33%
0.15
+61.29%
0.09
Net Interest Income
0.09
-71.10%
0.30
-50.08%
0.60
+78.40%
0.34
Interest Expense
0.07
-63.69%
0.18
+19.33%
0.15
+61.29%
0.09
Interest Income Non Operating
0.15
-68.33%
0.48
-36.25%
0.75
+74.71%
0.43
Interest Income
0.15
-68.33%
0.48
-36.25%
0.75
+74.71%
0.43
Other Income Expense
-1.83
+84.59%
-11.87
+90.01%
-118.82
+39.61%
-196.76
Other Non Operating Income Expenses
0.03
-96.33%
0.79
+100.65%
-120.84
+38.43%
-196.25
Gain On Sale Of Security
-0.14
-141.11%
0.34
-82.95%
2.01
+497.63%
-0.51
Tax Provision
0.00
-98.84%
0.26
+2490.00%
0.01
+900.00%
0.00
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.39
+85.32%
-2.66
-729.08%
0.42
+497.63%
-0.11
Net Income Including Noncontrolling Interests
-10.94
+79.69%
-53.86
+68.80%
-172.60
+28.33%
-240.81
Net Income From Continuing Operation Net Minority Interest
-10.94
+79.69%
-53.86
+68.80%
-172.60
+28.33%
-240.81
Net Income From Continuing And Discontinued Operation
-10.94
+79.69%
-53.86
+68.80%
-172.60
+28.33%
-240.81
Net Income Continuous Operations
-10.94
+79.69%
-53.86
+68.80%
-172.60
+28.33%
-240.81
Normalized Income
-9.47
+78.41%
-43.86
+74.82%
-174.19
+27.54%
-240.41
Net Income Common Stockholders
-10.94
+79.69%
-53.86
+68.80%
-172.60
+28.33%
-240.81
Diluted EPS
—
-52.80
+77.24%
-231.99
-7650.04%
-2.99
Basic EPS
—
-52.80
+77.24%
-231.99
-7650.04%
-2.99
Basic Average Shares
—
1.02
+37.10%
0.74
-99.08%
80.45
Diluted Average Shares
—
1.02
+37.10%
0.74
-99.08%
80.45
Diluted NI Availto Com Stockholders
-10.94
+79.69%
-53.86
+68.80%
-172.60
+28.33%
-240.81
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
6.71
-48.74%
13.10
-76.35%
55.39
-27.58%
76.47
Current Assets
6.05
-41.06%
10.27
-74.28%
39.92
-28.44%
55.79
Cash Cash Equivalents And Short Term Investments
3.28
-66.46%
9.77
-74.18%
37.82
-30.76%
54.61
Cash And Cash Equivalents
3.28
-66.46%
9.77
-69.53%
32.06
-1.89%
32.67
Other Short Term Investments
—
0.00
-100.00%
5.76
-73.74%
21.94
Receivables
2.49
+1860.63%
0.13
-72.75%
0.47
-14.81%
0.55
Accounts Receivable
2.31
0.00
—
—
Taxes Receivable
0.18
+45.67%
0.13
-72.75%
0.47
-14.81%
0.55
Prepaid Assets
0.28
-23.80%
0.37
-77.22%
1.64
+161.05%
0.63
Current Deferred Assets
—
—
—
0.00
Total Non Current Assets
0.66
-76.58%
2.83
-81.69%
15.46
-25.25%
20.68
Net PPE
0.58
-43.08%
1.02
+73.89%
0.59
-60.30%
1.48
Gross PPE
1.09
-27.97%
1.51
-52.31%
3.16
-17.86%
3.85
Accumulated Depreciation
-0.51
-3.47%
-0.49
+80.99%
-2.58
-8.50%
-2.38
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.91
-7.23%
0.98
-61.85%
2.57
-10.16%
2.87
Machinery Furniture Equipment
0.09
-78.16%
0.40
-11.43%
0.46
-46.60%
0.85
Leases
0.09
-29.03%
0.12
-8.15%
0.14
+0.00%
0.14
Goodwill And Other Intangible Assets
0.00
-100.00%
1.74
-88.23%
14.76
-0.14%
14.78
Other Intangible Assets
—
1.74
-88.23%
14.76
-0.14%
14.78
Investments And Advances
—
—
0.00
-100.00%
4.31
Other Investments
—
—
0.00
-100.00%
4.31
Non Current Prepaid Assets
0.08
+10.67%
0.07
-36.97%
0.12
-4.03%
0.12
Total Liabilities Net Minority Interest
9.90
+20.26%
8.23
-41.82%
14.15
-97.30%
524.60
Current Liabilities
6.33
-14.50%
7.40
-45.42%
13.56
+9.70%
12.36
Payables And Accrued Expenses
6.12
-14.64%
7.17
-21.79%
9.16
-21.52%
11.68
Payables
1.79
+43.11%
1.25
-79.10%
5.97
-20.79%
7.54
Other Payable
1.79
+43.11%
1.25
-79.10%
5.97
-20.79%
7.54
Current Accrued Expenses
4.33
-26.82%
5.92
+85.46%
3.19
-22.87%
4.14
Total Tax Payable
—
—
—
—
Current Debt And Capital Lease Obligation
0.21
-10.30%
0.23
-94.70%
4.39
+615.64%
0.61
Current Debt
—
—
4.24
—
Current Capital Lease Obligation
0.21
-10.30%
0.23
+47.47%
0.16
-74.27%
0.61
Current Deferred Liabilities
—
—
—
1.00
Other Current Liabilities
—
—
—
0.07
Total Non Current Liabilities Net Minority Interest
3.58
+328.26%
0.83
+39.87%
0.60
-99.88%
512.24
Long Term Debt And Capital Lease Obligation
0.43
-40.79%
0.73
+174.53%
0.27
-29.18%
0.38
Long Term Capital Lease Obligation
0.43
-40.79%
0.73
+174.53%
0.27
-29.18%
0.38
Other Non Current Liabilities
3.02
—
—
511.86
Preferred Securities Outside Stock Equity
—
—
0.00
-100.00%
511.86
Stockholders Equity
-3.19
-165.54%
4.86
-88.20%
41.23
+109.20%
-448.12
Common Stock Equity
-3.19
-165.54%
4.86
-88.20%
41.23
+109.20%
-448.12
Capital Stock
0.02
+90.91%
0.01
+22.22%
0.01
-78.05%
0.04
Common Stock
0.02
+90.91%
0.01
+22.22%
0.01
-78.05%
0.04
Share Issued
2.15
+94.70%
1.10
+23.22%
0.89
-98.89%
80.45
Ordinary Shares Number
2.15
+94.70%
1.10
+23.22%
0.89
-98.89%
80.45
Additional Paid In Capital
670.38
+0.58%
666.53
+0.76%
661.47
+5287.03%
12.28
Retained Earnings
-711.76
-1.56%
-700.82
-8.32%
-646.97
-36.32%
-474.60
Gains Losses Not Affecting Retained Earnings
3.44
+0.00%
3.44
+0.00%
3.44
+1.09%
3.40
Treasury Stock
—
0.00
0.00
-100.00%
0.07
Other Equity Adjustments
3.44
+0.00%
3.44
+0.00%
3.44
+1.09%
3.40
Total Equity Gross Minority Interest
-3.19
-165.54%
4.86
-88.20%
41.23
+109.20%
-448.12
Total Capitalization
-3.19
-165.54%
4.86
-88.20%
41.23
+109.20%
-448.12
Working Capital
-0.28
-109.59%
2.87
-89.12%
26.37
-39.29%
43.43
Invested Capital
-3.19
-165.54%
4.86
-89.30%
45.47
+110.15%
-448.12
Total Debt
0.64
-33.44%
0.97
-79.27%
4.66
+370.33%
0.99
Capital Lease Obligations
0.64
-33.44%
0.97
+127.29%
0.42
-57.11%
0.99
Net Tangible Assets
-3.19
-201.95%
3.13
-88.19%
26.48
+105.72%
-462.90
Tangible Book Value
-3.19
-201.95%
3.13
-88.19%
26.48
+105.72%
-462.90
Derivative Product Liabilities
0.12
+21.57%
0.10
-69.09%
0.33
0.00
Line Of Credit
—
0.00
-100.00%
4.24
0.00
Other Equity Interest
34.73
-2.74%
35.71
+53.40%
23.28
+114.97%
10.83
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-10.37
+63.93%
-28.74
+33.48%
-43.21
-0.90%
-42.82
Cash Flow From Continuing Operating Activities
-10.37
+63.93%
-28.74
+33.48%
-43.21
-0.90%
-42.82
Net Income From Continuing Operations
-10.94
+79.60%
-53.60
+68.94%
-172.59
+28.33%
-240.81
Depreciation Amortization Depletion
0.26
-29.36%
0.36
-46.04%
0.67
-13.68%
0.78
Depreciation
0.23
-31.09%
0.34
-47.46%
0.65
-14.04%
0.76
Amortization Cash Flow
0.02
+0.00%
0.02
+0.00%
0.02
+0.00%
0.02
Depreciation And Amortization
0.26
-29.36%
0.36
-46.04%
0.67
-13.68%
0.78
Amortization Of Intangibles
0.02
+0.00%
0.02
+0.00%
0.02
+0.00%
0.02
Other Non Cash Items
-0.08
-1500.00%
-0.01
-100.01%
44.83
+13361.83%
-0.34
Stock Based Compensation
-0.98
-108.96%
10.93
-13.87%
12.69
+254.13%
3.58
Asset Impairment Charge
1.72
-86.79%
13.00
0.00
0.00
Operating Gains Losses
0.01
-16.67%
0.02
+133.96%
-0.05
+97.21%
-1.90
Gain Loss On Investment Securities
—
—
0.04
—
Unrealized Gain Loss On Investment Securities
0.02
+109.91%
-0.22
-100.30%
74.83
-60.47%
189.32
Net Foreign Currency Exchange Gain Loss
0.00
0.00
+100.00%
-0.28
+85.32%
-1.90
Gain Loss On Sale Of PPE
0.01
-16.67%
0.02
-90.43%
0.19
0.00
Change In Working Capital
-0.38
-136.64%
1.04
+129.07%
-3.57
-154.98%
6.49
Change In Prepaid Assets
-2.28
-241.98%
1.61
+272.53%
-0.93
-125.53%
3.65
Change In Payables And Accrued Expense
1.90
+433.27%
-0.57
+78.33%
-2.63
-192.88%
2.84
Change In Payable
1.90
+433.27%
-0.57
+78.33%
-2.63
-192.88%
2.84
Investing Cash Flow
0.22
-96.36%
5.98
-72.00%
21.36
-26.46%
29.05
Cash Flow From Continuing Investing Activities
0.22
-96.36%
5.98
-72.00%
21.36
-26.46%
29.05
Net PPE Purchase And Sale
0.05
+340.00%
-0.02
-138.46%
0.05
+114.17%
-0.37
Purchase Of PPE
0.00
+100.00%
-0.02
-300.00%
-0.01
+98.37%
-0.37
Sale Of PPE
0.05
+1100.00%
0.00
-93.10%
0.06
0.00
Capital Expenditure
—
-0.02
-300.00%
-0.01
+98.37%
-0.37
Net Investment Purchase And Sale
0.00
-100.00%
5.76
-71.88%
20.49
-29.36%
29.00
Purchase Of Investment
—
—
—
0.00
Sale Of Investment
0.00
-100.00%
5.76
-71.88%
20.49
-29.36%
29.00
Net Intangibles Purchase And Sale
—
—
0.00
0.00
Purchase Of Intangibles
—
—
0.00
0.00
Net Other Investing Changes
0.02
-59.09%
0.04
+780.00%
0.01
+145.45%
-0.01
Financing Cash Flow
3.68
+685.47%
0.47
-97.80%
21.23
+7319.39%
-0.29
Cash Flow From Continuing Financing Activities
3.68
+685.47%
0.47
-97.80%
21.23
+7319.39%
-0.29
Net Issuance Payments Of Debt
3.73
+464.90%
0.66
-97.25%
24.04
+4154.13%
-0.59
Issuance Of Debt
3.86
-32.90%
5.75
-76.51%
24.48
0.00
Repayment Of Debt
-0.12
+97.54%
-5.09
-1046.40%
-0.44
+25.13%
-0.59
Long Term Debt Issuance
3.86
-23.57%
5.05
-75.07%
20.25
0.00
Long Term Debt Payments
-0.12
+26.47%
-0.17
+61.71%
-0.44
+25.13%
-0.59
Net Long Term Debt Issuance
3.73
-23.47%
4.88
-75.36%
19.80
+3439.80%
-0.59
Short Term Debt Issuance
0.00
-100.00%
0.70
-83.43%
4.24
0.00
Short Term Debt Payments
0.00
+100.00%
-4.92
0.00
0.00
Net Short Term Debt Issuance
0.00
+100.00%
-4.22
-199.58%
4.24
0.00
Net Common Stock Issuance
—
—
—
0.39
Cash Dividends Paid
0.00
0.00
0.00
0.00
Proceeds From Stock Option Exercised
0.01
0.00
-100.00%
0.09
-78.32%
0.39
Net Other Financing Charges
—
—
-2.78
—
Changes In Cash
-6.47
+70.95%
-22.29
-3501.29%
-0.62
+95.60%
-14.06
Effect Of Exchange Rate Changes
-0.01
-850.00%
0.00
0.00
0.00
Beginning Cash Position
9.77
-69.53%
32.06
-1.89%
32.67
-30.09%
46.74
End Cash Position
3.28
-66.46%
9.77
-69.53%
32.06
-1.89%
32.67
Free Cash Flow
-10.37
+63.96%
-28.77
+33.43%
-43.22
-0.06%
-43.19
Common Stock Issuance
—
—
—
0.39
Interest Paid CFF
-0.07
+66.32%
-0.19
-58.20%
-0.12
-31.18%
-0.09
Interest Received CFI
0.15
-23.23%
0.20
-75.88%
0.82
+90.49%
0.43
Issuance Of Capital Stock
—
—
—
0.39
Net Preferred Stock Issuance
—
—
—
0.00
Preferred Stock Issuance
—
—
—
0.00
Taxes Refund Paid
-0.00
+98.84%
-0.26
-2490.00%
-0.01
-117.86%
0.06
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category